Table 1.

Gefitinib IC50s for a panel of HNSCC cell lines as determined by a 5-d 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, corresponding EGFR gene and cell surface expression, and percentage of cells in G1 phase following 24-h treatment with 1 or 10 μmol/L of gefitinib

Cell lineIC50 (μmol/L gefitinib)Microarray signalEGFR expression
Cell cycle (% G1) μmol/L of gefitinib
MFIPositive (%)0110
UM-SCC-20.26759259936.578.887.9
HN40.16699289837.359.446.6
UM-SCC-80.069041110052.281.179.5
HN310.23631169866.976.682.3
MDA-15860.65681110043.047.965.8
UM-SCC-10A>101630046.840.541.5
UM-SCC-22B>1045249570.463.476.5
584>1055369141.845.856.4
1483>1068859236.233.935.3